2023
Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer
Cartmel B, Li F, Zhou Y, Gottlieb L, Lu L, Mszar R, Harrigan M, Ligibel J, Gogoi R, Schwartz P, Risch H, Irwin M. Randomized trial of exercise on cancer‐related blood biomarkers and survival in women with ovarian cancer. Cancer Medicine 2023, 12: 15492-15503. PMID: 37269192, PMCID: PMC10417064, DOI: 10.1002/cam4.6187.Peer-Reviewed Original ResearchConceptsExercise interventionOvarian cancerTrial of exerciseExercise-induced changesMin/weekGroup differencesSubset of participantsCause mortalityExercise groupOverall survivalStudy armsCA 125Randomized trialsBlood biomarkersBlood drawBreast cancerClinical significanceIGF-1Effect model analysisSecondary analysisBeneficial effectsCancerBiomarkersTrialsWomenIn silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer
Lu L, Ma W, Johnson C, Khan S, Irwin M, Pusztai L. In silico designed mRNA vaccines targeting CA-125 neoantigen in breast and ovarian cancer. Vaccine 2023, 41: 2073-2083. PMID: 36813666, PMCID: PMC10064809, DOI: 10.1016/j.vaccine.2023.02.048.Peer-Reviewed Original ResearchConceptsMRNA vaccinesOvarian cancerT cell responsesMutation-derived neoantigensT cell epitopesSARS-CoV-2Multiple neoantigensCytotoxic CD8Dendritic cellsCA 125Cancer vaccinesPatient survivalImmune responseCell epitopesNeoepitope peptidesNeoantigensVaccineCell responsesCancerBreastReverse vaccinologyCD8CD40LIFNNeoepitopes
2021
Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC)
Cartmel B, Hughes M, Ercolano EA, Gottlieb L, Li F, Zhou Y, Harrigan M, Ligibel JA, von Gruenigen VE, Gogoi R, Schwartz PE, Risch HA, Lu L, Irwin ML. Randomized trial of exercise on depressive symptomatology and brain derived neurotrophic factor (BDNF) in ovarian cancer survivors: The Women's Activity and Lifestyle Study in Connecticut (WALC). Gynecologic Oncology 2021, 161: 587-594. PMID: 33773809, PMCID: PMC8085084, DOI: 10.1016/j.ygyno.2021.02.036.Peer-Reviewed Original ResearchConceptsOvarian cancer survivorsCES-D scoresCancer survivorsOvarian cancerDepressive symptomatologyAC armStage III/IV ovarian cancerBaseline CES-D scoreTrial of exerciseEpidemiologic Studies Depression ScaleOvarian cancer patientsEffects of exerciseSix-month changesPrevalent mental disordersLower depressive symptomsExercise armSerum BrainNeurotrophin factorRandomized trialsNeurotrophic factorCancer patientsLifestyle StudyDepression ScalePhysical activityDepressive symptomsCross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers
Glubb DM, Thompson DJ, Aben K, Alsulimani A, Amant F, Annibali D, Attia J, Barricarte A, Beckmann MW, Berchuck A, Bermisheva M, Bernardini MQ, Bischof K, Bjorge L, Bodelon C, Brand AH, Brenton JD, Brinton LA, Bruinsma F, Buchanan DD, Burghaus S, Butzow R, Cai H, Carney ME, Chanock SJ, Chen C, Chen X, Chen Z, Cook LS, Cunningham JM, De Vivo I, deFazio A, Doherty JA, Dörk T, du Bois A, Dunning AM, Dürst M, Edwards T, Edwards RP, Ekici AB, Ewing A, Fasching PA, Ferguson S, Flanagan JM, Fostira F, Fountzilas G, Friedenreich CM, Gao B, Gaudet MM, Gawełko J, Gentry-Maharaj A, Giles GG, Glasspool R, Goodman MT, Gronwald J, Harris HR, Harter P, Hein A, Heitz F, Hildebrandt MAT, Hillemanns P, Høgdall E, Høgdall CK, Holliday EG, Huntsman DG, Huzarski T, Jakubowska A, Jensen A, Jones ME, Karlan BY, Karnezis A, Kelley JL, Khusnutdinova E, Killeen JL, Kjaer SK, Klapdor R, Köbel M, Konopka B, Konstantopoulou I, Kopperud RK, Koti M, Kraft P, Kupryjanczyk J, Lambrechts D, Larson MC, Le Marchand L, Lele S, Lester J, Li AJ, Liang D, Liebrich C, Lipworth L, Lissowska J, Lu L, Lu KH, Macciotta A, Mattiello A, May T, McAlpine JN, McGuire V, McNeish IA, Menon U, Modugno F, Moysich KB, Nevanlinna H, Odunsi K, Olsson H, Orsulic S, Osorio A, Palli D, Park-Simon TW, Pearce CL, Pejovic T, Permuth JB, Podgorska A, Ramus SJ, Rebbeck TR, Riggan MJ, Risch HA, Rothstein JH, Runnebaum IB, Scott RJ, Sellers TA, Senz J, Setiawan VW, Siddiqui N, Sieh W, Spiewankiewicz B, Sutphen R, Swerdlow AJ, Szafron L, Teo SH, Thompson PJ, Thomsen LCV, Titus L, Tone A, Tumino R, Turman C, Vanderstichele A, Edwards D, Vergote I, Vierkant RA, Wang Z, Wang-Gohrke S, Webb PM, Group F, Group F, White E, Whittemore A, Winham S, Wu X, Wu A, Yannoukakos D, Spurdle A, O'Mara T. Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 217-228. PMID: 33144283, DOI: 10.1158/1055-9965.epi-20-0739.Peer-Reviewed Original Research
2020
Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced ovarian cancer: A single-institution retrospective cohort study
Webster E, Dugan K, McNamara B, Lu L, Azodi M, Ratner E, Schwartz P, Menderes G. Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced ovarian cancer: A single-institution retrospective cohort study. Gynecologic Oncology 2020, 159: 131. DOI: 10.1016/j.ygyno.2020.05.163.Peer-Reviewed Original Research
2019
Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced-stage ovarian cancer
Dugan K, McNamara B, Lu L, Litkouhi B, Azodi M, Schwartz P, Ratner E, Menderes G, Silasi D. Surgical approach for interval debulking after neoadjuvant chemotherapy for treatment of advanced-stage ovarian cancer. Gynecologic Oncology 2019, 154: 152. DOI: 10.1016/j.ygyno.2019.04.358.Peer-Reviewed Original Research
2017
Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival
Yang JC, Risch E, Zhang M, Huang C, Huang H, Lu L. Association of tRNA methyltransferase NSUN2/IGF-II molecular signature with ovarian cancer survival. Future Oncology 2017, 13: 1981-1990. PMID: 28829218, DOI: 10.2217/fon-2017-0084.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, Clear CellAdenocarcinoma, MucinousAdultAgedAged, 80 and overBiomarkers, TumorCystadenocarcinoma, SerousEndometrial NeoplasmsFemaleFollow-Up StudiesHumansInsulin-Like Growth Factor IIMethyltransferasesMiddle AgedNeoplasm Recurrence, LocalOvarian NeoplasmsPrognosisSurvival RateConceptsOvarian cancer survivalIGF-IICancer survivalOvarian cancerDisease progression-free survivalMultivariate Cox regression modelProgression-free survivalRisk of deathCox regression modelIGF-II expressionClinical followSurvival analysisClinical implicationsIGFNormal tissuesHeterogeneous outcomesSurvivalCancerMolecular signaturesAssociationRegression modelsRNA sequencingSupNSUN2Relapse
2016
Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer
Fu Y, Biglia N, Wang Z, Shen Y, Risch HA, Lu L, Canuto EM, Jia W, Katsaros D, Yu H. Long non-coding RNAs, ASAP1-IT1, FAM215A, and LINC00472, in epithelial ovarian cancer. Gynecologic Oncology 2016, 143: 642-649. PMID: 27667152, PMCID: PMC5507336, DOI: 10.1016/j.ygyno.2016.09.021.Peer-Reviewed Original ResearchMeSH KeywordsAdaptor Proteins, Signal TransducingAdenocarcinoma, Clear CellAdultAgedAged, 80 and overCarcinoma, EndometrioidCarcinoma, Ovarian EpithelialHumansMiddle AgedNeoplasm GradingNeoplasm StagingNeoplasms, Cystic, Mucinous, and SerousNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisProportional Hazards ModelsReverse Transcriptase Polymerase Chain ReactionRNA, Long NoncodingYoung AdultConceptsEpithelial ovarian cancerOvarian cancerStage diseasePatient survivalGrade tumorsASAP1-IT1Survival associationsLong non-coding RNAsCox proportional hazards regression modelPrimary epithelial ovarian cancerProportional hazards regression modelsTumor samplesFresh frozen tumor samplesHigh expressionEarly-stage diseaseFavorable overall survivalLate-stage diseaseHazards regression modelsLow-grade tumorsHigh-grade tumorsOvarian cancer progressionNon-coding RNAsImportant biological actionsOverall survivalPoor prognosisLIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis
Lu L, Katsaros D, Canuto EM, Biglia N, Risch HA, Yu H. LIN-28B/let-7a/IGF-II axis molecular subtypes are associated with epithelial ovarian cancer prognosis. Gynecologic Oncology 2016, 141: 121-127. PMID: 26751131, DOI: 10.1016/j.ygyno.2015.12.035.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancer prognosisOvarian cancer prognosisMolecular subtypesCancer prognosisSurvival analysisMultivariate Cox regression modelKaplan-Meier survival curvesEpithelial ovarian cancer tissuesCox regression modelEpithelial ovarian cancerReduced relapse riskOvarian cancer tissuesIGF-II mRNAQuantitative reverse transcription PCRRelapse riskReverse transcription-PCROvarian cancerBetter survivalCancer tissuesLin-28BSurvival curvesClinical implicationsIGFPrognosisSubtypes
2015
Clinical characteristics and survival outcomes in BRCA1 -methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies.
Kalachand R, Ruscito I, Dimitrova D, Benedetti Panici P, Sehouli J, Olek S, Braicu E, Lu L, Katsaros D, Yu H, Carey M, Broaddus R, Lu K, Mills G, Harrell M, Agnew K, Swisher E, Grogan W, Stordal B, Hennessy B. Clinical characteristics and survival outcomes in BRCA1 -methylated epithelial ovarian cancer (Bmeth-OC): A pooled analysis of data for 1,278 patients across five studies. Journal Of Clinical Oncology 2015, 33: 5526-5526. DOI: 10.1200/jco.2015.33.15_suppl.5526.Peer-Reviewed Original Research
2013
An insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival
Lu L, Risch E, Deng Q, Biglia N, Picardo E, Katsaros D, Yu H. An insulin-like growth factor-II intronic variant affects local DNA conformation and ovarian cancer survival. Carcinogenesis 2013, 34: 2024-2030. PMID: 23677070, DOI: 10.1093/carcin/bgt168.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor IIIGF-II expressionPatient survivalGrowth factor IIPresence of carboplatinChemotherapy responseOvarian cancerCox proportional hazards regression modelKaplan-Meier survival curvesProportional hazards regression modelsFactor IIOvarian cancer tissue samplesIGF-II genotypeAdjusted hazard ratioOvarian cancer survivalHazards regression modelsCommercial enzyme-linked immunosorbentQuantitative reverse transcription polymerase chain reactionReverse transcription-polymerase chain reactionOvarian cancer developmentTranscription-polymerase chain reactionCancer tissue samplesEnzyme-linked immunosorbentHazard ratioSNP genotyping assays
2012
Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer
Lu L, Katsaros D, Mayne ST, Risch HA, Benedetto C, Canuto EM, Yu H. Functional study of risk loci of stem cell-associated gene lin-28B and associations with disease survival outcomes in epithelial ovarian cancer. Carcinogenesis 2012, 33: 2119-2125. PMID: 22822098, DOI: 10.1093/carcin/bgs243.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Ovarian EpithelialCircular DichroismCohort StudiesFemaleFollow-Up StudiesHumansMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialNeoplastic Stem CellsNucleic Acid ConformationOvarian NeoplasmsPolymorphism, Single NucleotidePrognosisPromoter Regions, GeneticQuantitative Trait LociReal-Time Polymerase Chain ReactionReverse Transcriptase Polymerase Chain ReactionRisk FactorsRNA, MessengerRNA-Binding ProteinsSurvival RateConceptsSingle nucleotide polymorphismsOvarian cancerEpithelial ovarian cancer survivalCancer-related risk factorsEpithelial ovarian cancerOvarian cancer survivalOvarian cancer prognosisHigher mortality riskCell-associated markersPrimary EOC tissuesLin-28BStem cell-associated markersAssociation of genotypesDominant modelPatient survivalSurvival outcomesBorderline significanceEOC tissuesCancer survivalRisk factorsReal-time PCRMortality riskCancer prognosisMultivariate analysisPotential biomarkers
2011
A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer
Ratner ES, Keane FK, Lindner R, Tassi RA, Paranjape T, Glasgow M, Nallur S, Deng Y, Lu L, Steele L, Sand S, Muller RU, Bignotti E, Bellone S, Boeke M, Yao X, Pecorelli S, Ravaggi A, Katsaros D, Zelterman D, Cristea MC, Yu H, Rutherford TJ, Weitzel JN, Neuhausen SL, Schwartz PE, Slack FJ, Santin AD, Weidhaas JB. A KRAS variant is a biomarker of poor outcome, platinum chemotherapy resistance and a potential target for therapy in ovarian cancer. Oncogene 2011, 31: 4559-4566. PMID: 22139083, PMCID: PMC3342446, DOI: 10.1038/onc.2011.539.Peer-Reviewed Original ResearchMeSH Keywords3' Untranslated RegionsAgedAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorBRCA1 ProteinBRCA2 ProteinCarboplatinCell Line, TumorCell SurvivalDrug Resistance, NeoplasmFemaleGenotypeHumansKaplan-Meier EstimateMiddle AgedMultivariate AnalysisMutationNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelPolymorphism, Single NucleotidePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRNA InterferenceTreatment OutcomeConceptsEpithelial ovarian cancerEOC patientsKRAS-variantOvarian cancerPoor outcomeCancer riskTumor biologyPlatinum resistanceComplete clinical dataBiomarkers of outcomeDirect targetingEOC cell growthKnown BRCA mutationsFuture treatment approachesSubset of tumorsPlatinum chemotherapy resistanceCell linesNeoadjuvant chemotherapyBRCA mutationsClinical dataTreatment approachesChemotherapy resistanceKRAS oncogeneMultivariate analysisPatients
2010
IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics.
Qian B, Katsaros D, Lu L, Canuto EM, Benedetto C, Beeghly-Fadiel A, Yu H. IGF-II promoter specific methylation and expression in epithelial ovarian cancer and their associations with disease characteristics. Oncology Reports 2010, 25: 203-13. PMID: 21109978, PMCID: PMC3075064, DOI: 10.3892/or_00001062.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overDisease-Free SurvivalDNA MethylationFemaleGene Expression Regulation, NeoplasticHumansInsulin-Like Growth Factor IIMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPromoter Regions, GeneticReverse Transcriptase Polymerase Chain ReactionConceptsInsulin-like growth factor IIEpithelial ovarian cancerOvarian cancerDisease progressionResidual tumor sizeIGF-II peptideFresh tumor samplesIGF-II expressionPromoter-specific expressionIGF-II mRNAGrowth factor IIIGF-II promotersLower mRNA expressionOverall survivalAggressive diseasePoor prognosisTumor sizeDisease characteristicsMethylation-specific PCRTumor gradeTreatment responseIGF-II transcriptionPromoter-specific methylationClinical implicationsCancerLet-7a regulation of insulin-like growth factors in breast cancer
Lu L, Katsaros D, Zhu Y, Hoffman A, Luca S, Marion CE, Mu L, Risch H, Yu H. Let-7a regulation of insulin-like growth factors in breast cancer. Breast Cancer Research And Treatment 2010, 126: 687-694. PMID: 20848182, DOI: 10.1007/s10549-010-1168-5.Peer-Reviewed Original ResearchConceptsIGF expressionBreast cancerOvarian cancerInsulin-like growth factorDisease-free survivalCancer cellsAction of IGFBreast cancer patientsExpression of IGFHigh-grade tumorsIGF-II expressionPR-negative cancerLet-7aQuantitative methylation-specific PCRBreast cancer samplesOverall survivalFavorable prognosisPatient survivalCancer patientsGrade tumorsIGF mRNAsMethylation-specific PCRDisease featuresCancerCancer samplesA KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk
Ratner E, Lu L, Boeke M, Barnett R, Nallur S, Chin LJ, Pelletier C, Blitzblau R, Tassi R, Paranjape T, Hui P, Godwin AK, Yu H, Risch H, Rutherford T, Schwartz P, Santin A, Matloff E, Zelterman D, Slack FJ, Weidhaas JB. A KRAS-Variant in Ovarian Cancer Acts as a Genetic Marker of Cancer Risk. Cancer Research 2010, 70: 6509-6515. PMID: 20647319, PMCID: PMC2923587, DOI: 10.1158/0008-5472.can-10-0689.Peer-Reviewed Original ResearchConceptsOvarian cancerKRAS-variantOC patientsCancer riskRisk of OCIndependent case-control analysesCase-control studyOvarian cancer syndromeCase-control analysisFamily membersAdvanced diseaseWomen's cancersRisk factorsBRCA2 mutationsHBOC patientsOC casesIndependent cohortHBOC familiesHereditary breastSolid tumorsCancer syndromesKRAS oncogeneVariant allelesPatientsCancer
2009
Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II
Lu L, Katsaros D, Shaverdashvili K, Qian B, Wu Y, de la Longrais IA, Preti M, Menato G, Yu H. Pluripotent factor lin-28 and its homologue lin-28b in epithelial ovarian cancer and their associations with disease outcomes and expression of let-7a and IGF-II. European Journal Of Cancer 2009, 45: 2212-2218. PMID: 19477633, DOI: 10.1016/j.ejca.2009.05.003.Peer-Reviewed Original ResearchConceptsEpithelial ovarian cancerIGF-II expressionIGF-IIOvarian cancerPrimary epithelial ovarian cancerInsulin-like growth factor IIUnfavourable prognostic markerOvarian cancer progressionPotential therapeutic targetLin-28BGrowth factor IIStem cellsIGFBP-3Overall survivalDisease progressionPrognostic markerDisease outcomeDisease featuresTherapeutic targetTumor growthTumor samplesFactor IICancer treatmentCancer progressionGrowth factor
2008
Klotho Expression in Epithelial Ovarian Cancer and its Association with Insulin-Like Growth Factors and Disease Progression
Lu L, Katsaros D, Wiley A, de la Longrais IA, Puopolo M, Yu H. Klotho Expression in Epithelial Ovarian Cancer and its Association with Insulin-Like Growth Factors and Disease Progression. Cancer Investigation 2008, 26: 185-192. PMID: 18259951, DOI: 10.1080/07357900701638343.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsBiomarkers, TumorCystadenocarcinoma, SerousDisease ProgressionEpithelial CellsFemaleFollow-Up StudiesGene Expression Regulation, NeoplasticGlucuronidaseHumansInsulin-Like Growth Factor Binding Protein 3Insulin-Like Growth Factor IInsulin-Like Growth Factor IIKlotho ProteinsMiddle AgedNeoplasm StagingOvarian NeoplasmsPrognosisReverse Transcriptase Polymerase Chain ReactionRNA, NeoplasmSurvival RateConceptsEpithelial ovarian cancerKlotho expressionOvarian cancer progressionDisease progressionOvarian cancerCox proportional hazards regression modelTumor tissueProportional hazards regression modelsCancer progressionInsulin-like growth factorResidual tumor sizeAction of IGFOvarian cancer patientsExpression of IGFHazards regression modelsOvarian cancer prognosisEpithelial ovarian cancer progressionExpression of totalFresh tumor tissueWarrants further elucidationUnderwent surgeryIGFBP-3Patient ageClinical followTumor histology
2007
Hypermethylation of let-7a-3 in Epithelial Ovarian Cancer Is Associated with Low Insulin-like Growth Factor-II Expression and Favorable Prognosis
Lu L, Katsaros D, de la Longrais IA, Sochirca O, Yu H. Hypermethylation of let-7a-3 in Epithelial Ovarian Cancer Is Associated with Low Insulin-like Growth Factor-II Expression and Favorable Prognosis. Cancer Research 2007, 67: 10117-10122. PMID: 17974952, DOI: 10.1158/0008-5472.can-07-2544.Peer-Reviewed Original ResearchConceptsInsulin-like growth factor IIPossible epigenetic regulationLet-7 regulationEpithelial ovarian cancerLet-7aRole of miRNAsActivity of mRNAPromoter CpG island methylationCpG island methylationTumor suppressor geneIGF-II expressionMiRNA genesSmall RNAsEpigenetic regulationOvarian cancerDNA methylationCpG islandsMethylation-specific PCRReal-time reverse transcription PCRReverse transcription-PCRReal-time methylation-specific PCRSuppressor geneIsland methylationMethylationMiRNA expressionIGF-I in epithelial ovarian cancer and its role in disease progression
Brokaw J, Katsaros D, Wiley A, Lu L, Su D, Sochirca O, de la Longrais IA, Mayne S, Risch H, Yu H. IGF-I in epithelial ovarian cancer and its role in disease progression. Growth Factors 2007, 25: 346-354. PMID: 18236213, DOI: 10.1080/08977190701838402.Peer-Reviewed Original ResearchConceptsIGF-I transcriptsDisease progressionOvarian cancerTumor progressionEpithelial ovarian cancer patientsIGF-I mRNA expressionInsulin-like growth factorParacrine/autocrine regulationIGF-I activityEpithelial ovarian cancerIGF-I actionOvarian cancer patientsFresh tumor samplesIGF-I expressionIGF-I mRNAOvarian cancer progressionEnzyme-linked immunosorbentParacrine/autocrineTotal IGFFree IGFClinicopathologic featuresCA polymorphismCancer patientsReal-time PCRElevated risk